Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical Inc is expected to benefit from several potential upside drivers, including faster-than-anticipated growth in the spine market and increased sales from its Enabling Technologies segment, which collectively may enhance profit margins. The company demonstrates strong financial fundamentals, highlighted by impressive free cash flow growth and an 8% free cash flow yield, alongside trading at valuations below historical levels and in line with industry peers. Despite a recent miss in consensus expectations for quarterly revenue, ongoing profit potential remains, suggesting a favorable outlook for the company's performance in the coming years.

Bears say

Globus Medical Inc. faces several fundamental risks impacting its financial outlook, primarily stemming from anticipated slower growth in the spine market and potential revenue dis-synergies following the NuVasive merger. Additionally, the company may encounter challenges such as lower-than-expected sales in its Enabling Technologies segment, a shift in competitive dynamics, and the possibility of disappointing key product launches, all contributing to a constrained growth trajectory. This combination of factors, along with concerns regarding operating margin deterioration, raises significant questions about the sustainability of the company's revenue and profitability moving forward.

Globus Medical (GMED) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 11 analysts, Globus Medical (GMED) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.